Physician profile
Maya Spodik
NPI 1356559850
$14,223.76
in general payments reported to CMS, 2019-2025
29 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,283 · 2020: $2,929 · 2021: $1,458 · 2022: $1,389 · 2023: $1,114 · 2024: $1,022 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,164.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,489.46 | 2019-2020 | |
| Abbvie INC. | $1,369.66 | 2019-2025 | Linzess, Skyrizi, Viberzi |
| Gilead Sciences, INC. | $1,159.64 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $812.40 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Janssen Biotech, INC. | $574.29 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $497.24 | 2022-2025 | |
| Redhill Biopharma INC. | $463.50 | 2020-2024 | Talicia, Movantik, Aemcolo |
| Takeda Pharmaceuticals U.S.A., INC. | $390.21 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $357.78 | 2020-2024 | Linzess |
| Qol Medical, LLC | $340.94 | 2019-2025 | Sucraid |
| Celgene Corporation | $270.52 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $233.10 | 2023-2025 | Zenpep, Vowst |
| Merck Sharp & Dohme LLC | $203.68 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $142.28 | 2020-2023 | |
| Braintree Laboratories, INC. | $128.41 | 2020-2023 | Sutab |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $125.68 | 2022-2025 | |
| Ardelyx, INC. | $118.91 | 2023-2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $82.33 | 2024-2025 | Voquezna |
| Vivus LLC | $78.78 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $76.14 | 2019-2023 | Ocaliva |
| Evoke Pharma, INC. | $68.02 | 2022-2024 | Gimoti |
| Lilly USA, LLC | $67.19 | 2024 | Omvoh |
| Shionogi INC | $45.16 | 2019 | |
| Axonics, INC. | $34.49 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $25.81 | 2025 | Iqirvo |
| Meridian Bioscience INC. | $24.92 | 2024 | |
| Exact Sciences Corporation | $17.60 | 2025 | Cologuard Collection Kit |
| Mauna Kea Technologies, INC. | $13.09 | 2020 | |
| Alfasigma USA, INC. | $12.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Spodik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.